Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


13.01.2025

3 Am J Hematol
16 Ann Hematol
6 Blood
1 Cancer
1 Cancer Lett
5 Eur J Haematol
1 Exp Hematol
1 Genomics
1 J Biol Chem
1 J Clin Oncol
4 J Pediatr Hematol Oncol
1 Leuk Lymphoma
5 Leukemia
1 Oncogene


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. BUTLER JT, Yashar WM, Swords R
    Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.
    Am J Hematol. 2025 Jan 7. doi: 10.1002/ajh.27586.
    PubMed         Abstract available

  2. KANTARJIAN H, Short NJ, Jain N, Haddad FG, et al
    Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2025 Jan 5. doi: 10.1002/ajh.27576.
    PubMed         Abstract available

  3. BATALLER A, Loghavi S, Gerstein Y, Bazinet A, et al
    Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
    Am J Hematol. 2023;98:1780-1790.
    PubMed         Abstract available


    Ann Hematol

  4. JAFARI PA, Bagheri R, Lavasani S, Goudarzi S, et al
    DNMT3A-R882: a mutation with many paradoxes.
    Ann Hematol. 2024;103:4981-4988.
    PubMed         Abstract available

  5. HAN X, Liu W, Kang Z, Li D, et al
    Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis.
    Ann Hematol. 2024;103:4943-4952.
    PubMed         Abstract available

  6. SUN Y, Wang Q, Zhang Z, Wang Q, et al
    Distinct clinical profiles and patient outcomes in aCML and CNL.
    Ann Hematol. 2024;103:5325-5332.
    PubMed         Abstract available

  7. LEE BJ, Griffin SP, Doh J, Ciurea SO, et al
    Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
    Ann Hematol. 2024;103:5395-5403.
    PubMed         Abstract available

  8. PUZO CJ, Hager KM, Rinder HM, Weinberg OK, et al
    Overall survival in TP53-mutated AML and MDS.
    Ann Hematol. 2024;103:5359-5369.
    PubMed         Abstract available

  9. CUI K, Zhang S, Wang Q, Wei Y, et al
    Prognostic significance of early nk cell recovery in pediatric t-cell replete allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:5769-5780.
    PubMed         Abstract available

  10. KOUIDRI K, Acker F, Toenges R, Pfaff S, et al
    Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.
    Ann Hematol. 2024;103:5387-5393.
    PubMed         Abstract available

  11. BIN T, Tang J, Lu B, Xu XJ, et al
    Construction of AML prognostic model with CYP2E1 and GALNT12 biomarkers based on golgi- associated genes.
    Ann Hematol. 2024;103:5297-5314.
    PubMed         Abstract available

  12. TAUVERON-JALENQUES U, Sarr K, Guieze R, Giordano C, et al
    Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.
    Ann Hematol. 2024;103:5985-5988.
    PubMed         Abstract available

  13. MATSUKAWA T, Onozawa M, Kondo T, Kanaya M, et al
    FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
    Ann Hematol. 2024;103:5333-5340.
    PubMed         Abstract available

  14. BUZZATTI E, Botti C, Presicci R, Mauro C, et al
    A fatal case of peritonitis due to colonic localization of acute myeloid leukemia.
    Ann Hematol. 2025 Jan 7. doi: 10.1007/s00277-024-06172.
    PubMed         Abstract available

  15. JIN S, Chang M, Feng L, Hao Y, et al
    PEG-rhG-CSF versus rhG-CSF in supporting neutrophil recovery after induction chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 8. doi: 10.1007/s00277-025-06183.
    PubMed         Abstract available

  16. JIMBO K, Ishigaki T, Sakashita M, Andoh S, et al
    Prognosis of aggressive adult T-cell leukemia/lymphoma with central nervous system infiltration and utility of CD7 versus CADM1 flowcytometric plots of cerebrospinal fluid.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-025-06186.
    PubMed         Abstract available

  17. YOUSEFI A, Levin MD, Cornelissen JJ, Westerweel PE, et al
    Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06170.
    PubMed         Abstract available

  18. SHAKEEL L, Khaliq N, Shaukat A, Khan A, et al
    The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06121.
    PubMed         Abstract available

  19. SCHULZ F, Roggenbuck C, Kundgen A, Kasprzak A, et al
    Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
    Ann Hematol. 2025 Jan 11. doi: 10.1007/s00277-025-06196.
    PubMed         Abstract available


    Blood

  20. PURVIS K, Zhou Y, Karol SE, Rubnitz JE, et al
    Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
    Blood. 2025;145:190-201.
    PubMed         Abstract available

  21. DING YY, Sussman JH, Madden K, Loftus JP, et al
    Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
    Blood. 2025 Jan 7:blood.2024026482. doi: 10.1182/blood.2024026482.
    PubMed         Abstract available

  22. PASSET M, Kim R, Clappier E
    Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.
    Blood. 2024 Dec 30:blood.2023022919. doi: 10.1182/blood.2023022919.
    PubMed         Abstract available

  23. MILLMAN SE, Chaves-Perez A, Janaki-Raman S, Ho YJ, et al
    alpha-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia.
    Blood. 2024 Dec 27:blood.2024025245. doi: 10.1182/blood.2024025245.
    PubMed         Abstract available

  24. ESCHERICH CS, Moriyama T, Li Z, Hsiao Y, et al
    DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Dec 27:blood.2024026085. doi: 10.1182/blood.2024026085.
    PubMed         Abstract available

  25. NYGREN PJ, Bouhlal JOV, Jokinen E, Forsten S, et al
    High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia.
    Blood. 2025 Jan 10:blood.2024025286. doi: 10.1182/blood.2024025286.
    PubMed         Abstract available


    Cancer

  26. WANG L, Chen Y, Zang M, Zhou J, et al
    Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia.
    Cancer. 2025;131:e35717.
    PubMed         Abstract available


    Cancer Lett

  27. PEI HZ, Guo Y, Zhao Y, Zhang D, et al
    FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia.
    Cancer Lett. 2025;611:217446.
    PubMed         Abstract available


    Eur J Haematol

  28. ZALAPA-SOTO J, Rios-Olais FA, Chacon-Rangel LC, Mora-Canas A, et al
    Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study.
    Eur J Haematol. 2025 Jan 7. doi: 10.1111/ejh.14381.
    PubMed         Abstract available

  29. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14383.
    PubMed         Abstract available

  30. BERTON G, Hospital MA, Garciaz S, Rouzaud C, et al
    Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14366.
    PubMed         Abstract available

  31. BENOIT TM, Bachofner A, Wolfensberger N, Zaugg-Berger Y, et al
    Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.
    Eur J Haematol. 2025;114:315-324.
    PubMed         Abstract available

  32. BRESSER H, Schmoor C, Grishina O, Pfeifer D, et al
    Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
    Eur J Haematol. 2025;114:231-237.
    PubMed         Abstract available


    Exp Hematol

  33. AMOR AR, Enlund S, Sinha I, Jiang Q, et al
    A Distinct Alternative mRNA Splicing Profile Identifies the Oncogenic CD44 Transcript Variant 3 in KMT2A-Rearranged Pediatric T-cell Acute Lymphoblastic Leukemia Cells.
    Exp Hematol. 2025 Jan 8:104712. doi: 10.1016/j.exphem.2025.104712.
    PubMed         Abstract available


    Genomics

  34. WENLI Y, Wei W, Yubiao P, Hua H, et al
    ARF3 as a novel biomarker and target in acute myeloid leukemia: Insights from pan-cancer analysis.
    Genomics. 2025 Jan 3:110984. doi: 10.1016/j.ygeno.2024.110984.
    PubMed         Abstract available


    J Biol Chem

  35. WU T, Sun Y, Wang D, Isaji T, et al
    The acetylglucosaminyltransferase GnT-? regulates erythroid differentiation through ERK/MAPK signaling.
    J Biol Chem. 2024;300:108010.
    PubMed         Abstract available


    J Clin Oncol

  36. GYURKOCZA B, Nath R, Seropian S, Choe H, et al
    Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
    J Clin Oncol. 2025;43:201-213.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  37. SALIK I, Blizard AJ, Abramov R, Khan A, et al
    A Survey of Sedation Practices for Adolescents and Young Adults With Acute Lymphoblastic Leukemia Undergoing Lumbar Puncture.
    J Pediatr Hematol Oncol. 2025 Jan 10. doi: 10.1097/MPH.0000000000002983.
    PubMed         Abstract available

  38. GAUR BK, Varshney C, Singh RR, Soneja P, et al
    A Neonate Presenting With Large Abdominal Mass: A Rare Case of Congenital Leukemia.
    J Pediatr Hematol Oncol. 2025 Jan 8. doi: 10.1097/MPH.0000000000002991.
    PubMed         Abstract available

  39. CAO K, Luo X, Li D, Chen X, et al
    Clonorchiasis, Marked Eosinophilia, and the Lack of Blasts in the Circulation Delaying the Diagnosis of Pediatric B-Lymphocytic Leukemia.
    J Pediatr Hematol Oncol. 2025 Jan 6. doi: 10.1097/MPH.0000000000002989.
    PubMed         Abstract available

  40. YALCIN GUNGOREN E, Koc B, Zulfikar B
    Comparison of Capizzi and High-dose Methotrexate Approaches in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol. 2025 Jan 6. doi: 10.1097/MPH.0000000000002995.
    PubMed         Abstract available


    Leuk Lymphoma

  41. SENAPATI J, Kantarjian H, Habib D, Haddad FG, et al
    Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
    Leuk Lymphoma. 2025 Jan 10:1-12. doi: 10.1080/10428194.2025.2449582.
    PubMed         Abstract available


    Leukemia

  42. SHAHSWAR R, Gabdoulline R, Krueger K, Wichmann M, et al
    A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
    Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501.
    PubMed         Abstract available

  43. SHIMOSATO Y, Yamamoto K, Jia Y, Zhang W, et al
    NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation.
    Leukemia. 2025;39:75-86.
    PubMed         Abstract available

  44. STRULLU M, Caye-Eude A, Robert E, Renard JM, et al
    CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL.
    Leukemia. 2025;39:64-74.
    PubMed         Abstract available

  45. JACOBY MA, Duncavage ED, Khanna A, Chang GS, et al
    Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
    Leukemia. 2025;39:166-177.
    PubMed         Abstract available

  46. LI Z, Fierstein S, Tanaka-Yano M, Frenis K, et al
    The epigenetic state of the cell of origin defines mechanisms of leukemogenesis.
    Leukemia. 2025;39:87-97.
    PubMed         Abstract available


    Oncogene

  47. ZHANG C, Hao T, Bortoluzzi A, Chen MH, et al
    Sex-dependent differences in hematopoietic stem cell aging and leukemogenic potential.
    Oncogene. 2024 Nov 1. doi: 10.1038/s41388-024-03197.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.